Dose-dependent effects of pharmaceutical treatments on bone matrix properties in ovariectomized rats

Lamya Karim a,*, Andrea Kwaczala b, Deepak Vashishth c, Stefan Judex d

a Department of Bioengineering, University of Massachusetts Dartmouth, Dartmouth, MA, USA
b Department of Biomedical Engineering, Western New England University, Springfield, MA, USA
c Department of Biomedical Engineering, Rensselaer Polytechnic Institute, Troy, NY, USA
d Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, USA

ARTICLE INFO

Keywords:
- Alendronate
- Parathyroid hormone
- Osteocalcin
- Osteopontin
- Advanced glycation end-products

ABSTRACT

As both anabolic and anti-catabolic osteoporosis drugs affect bone formation and resorption processes, they may contribute to bone’s overall mechanical behavior by altering the quality of the bone matrix. We used an ovariectomized rat model and a novel fracture mechanics approach to investigate whether treatment with an anabolic (parathyroid hormone) or anti-catabolic (alendronate) osteoporosis drugs will alter the organic and mineral matrix components and consequently cortical bone fracture toughness. Ovariectomized (at 5 months age) rats were treated with either parathyroid hormone or alendronate at low and high doses for 6 months (age 6–12 months). Specifically, treatment groups included untreated ovariectomized controls (n = 9), high-dose alendronate (n = 10), low-dose alendronate (n = 9), high-dose parathyroid hormone (n = 10), and low-dose parathyroid hormone (n = 9). After euthanasia, cortical microbeams from the lateral quadrant were extracted, notched, and tested in 3-point bending to measure fracture toughness. Portions of the bone were used to measure changes in the 1) organic matrix through quantification of advanced glycation end-products (AGEs) and non-collagenous proteins, and 2) mineral matrix through assessment of mineral crystallinity. Compared to the ovariectomized group, rats treated with high doses of parathyroid hormone and alendronate had significantly increased cortical bone fracture toughness, which corresponded primarily to increased non-collagenous proteins while there was no change in AGEs. Additionally, low-dose PTH treatment increased matrix crystallinity and decreased AGE levels. In summary, ovariectomized rats treated with pharmaceutical drugs had increased non-collagenous matrix proteins and improved fracture toughness compared to controls. Further investigation is required for different doses and longer treatment periods.

1. Introduction

Bone’s fracture resistance is influenced by properties related to bone quantity (e.g., mass) and bone quality (e.g., geometry, tissue matrix) (Boskey and Imbert, 2017). Although the effects of bone mass and geometry on skeletal mechanics and fragility have been investigated extensively (Karim et al., 2013a, 2013b), there is far less information available on the effects of the tissue matrix on bone’s mechanical properties, particularly in cortical bone. Gaining insight into this relationship is important because the bone matrix can undergo substantial changes with aging or with the onset of clinical conditions such as postmenopausal osteoporosis (Sroga and Vashishth, 2012; Osterhoff et al., 2016).

Post-menopausal osteoporosis has commonly been simulated by an ovariectomized (OVX) animal model, in particular the OVX rat (Thompson et al., 1995). Osteoporosis can be treated by pharmaceutical drugs including bisphosphonates and parathyroid hormone, both of which can alter bone’s matrix composition and have direct consequences on bone’s mechanical behavior (Jerome et al., 2001; Allen and Burr, 2011). Bisphosphonates, such as alendronate (ALN), are a group of anti-remodeling drugs that impair the action of osteoclasts on the bone surface which suppress bone resorption (Masarachia et al., 1996; Boivin and Meunier, 2002). This class of drugs induces morphological changes in osteoclasts and forces early cell apoptosis to prevent further bone loss (Masarachia et al., 1996). The decreased resorption may consequently increase overall bone mass (Boivin and Meunier, 2002) and decrease...
fracture risk (Cummings et al., 1998; Black et al., 2000; Axelson et al., 2017). In contrast, administration of intermittent parathyroid hormone (PTH), anabolic hormone treatment, stimulates osteoblasts and subsequently increases bone formation, outweighing the resorption process (Girotra et al., 2006; Gesty-Palmer et al., 2009). As a result, PTH treatment can increase bone mass and decrease fracture risk in patients (Neer et al., 2001).

Both ALN and PTH directly affect bone’s resorptive and formative activities, and consequently, bone’s matrix components. The dominant constituents of bone’s matrix are inorganic hydroxyapatite mineral and organic proteins including type I collagen and non-collagenous proteins (e.g., osteocalcin, osteopontin) (Burr and Allen, 2013). Type I collagen can undergo numerous biochemical modifications including non-enzymatic glycation, which is a spontaneous reaction involving extra-cellular sugars and amino acid residues that result in the formation of chemical adducts and crosslinks known as advanced glycation end-products (AGEs). The accumulation of AGEs may correlate with a deterioration in bone’s overall mechanical properties (Vashishth et al., 2001, Hernandez et al., 2005, Tang et al., 2007, Garnero, 2012, Karim et al., 2013a, 2013b).

A number of studies indicate that AGE accumulation is associated with reduced bone formation (Yang et al., 2016), resorption (Valcourt 2013b), as well as deteriorated bone stiffness, toughness, other post-yield mechanical properties, and indentation properties (Wang et al., 2002, Nyman et al., 2006; Nyman et al., 2007; Viguet-Carrin et al., 2008; Tang et al., 2009; Poundarik et al., 2015; Karim et al., 2018; Hunt et al., 2019; Merlo et al., 2020). Additionally, the non-collagenous proteins osteopontin and osteocalcin can affect bone’s mechanical behavior. These proteins are involved in mineralization (Glowacki et al., 1991; Goldstein et al., 1993; Ducy et al., 1996; Fantner et al., 2005), bone resorptive and formative activities ( Boskey et al., 1998, Kavukcuoglu et al., 2009, Sroga et al., 2011a, 2011b, Sroga and Vashishth, 2012), and together act to link the organic-inorganic interface in bone and hold mineralized collagen fibers together thereby enhancing bone toughness (Hara et al., 2007; Poundarik et al., 2012; Bailey et al., 2017; Nikel et al., 2018; Poundarik et al., 2018).

The goal of this work was to understand how alterations in bone’s organic matrix impact bone fracture toughness, a measure of bone’s inherent ability to resist crack initiation and propagation (Vashishth, 2004; Ural and Vashishth, 2014). To accomplish this goal, we used an OVX rat model to stimulate bone resorption paired with different doses of ALN and PTH treatment to manipulate bone tissue quality across a wide spectrum. Specifically, using high doses of these drugs that are beyond clinically-relevant doses allowed us to investigate how alterations in bone’s organic and inorganic matrix components may impact bone fracture toughness. Previous data demonstrated that administration of ALN and PTH in an OVX model or in osteoporosis can alter 1) bone’s organic matrix through changes in type I collagen by the accumulation of AGEs (Saito et al., 2011; Kimura et al., 2017), 2) non-collagenous proteins such as osteocalcin and osteopontin (Kurland et al., 2000; Chiang et al., 2011; Shao et al., 2017), and/or 3) bone’s mineral (Chesnut et al., 1995; Schwarz et al., 2012). We hypothesized that both ALN and PTH treatments will improve bone fracture toughness through alterations in bone matrix quality including both the mineral and organic matrix.

2. Methods

2.1. Experimental drug treatment

As the effects of ovarectomy on bone properties, including fracture toughness, are already well established in the literature (Camargos et al., 2015; Yu et al., 2015; Massie et al., 2021), we focused on comparing drug-treated OVX rats with non-treated OVX controls. The OVX procedure was performed by Charles River Laboratories at 5 months of age for all groups and drug treatment administration began after acclimatization at 6 months of age by subcutaneous injection. Selection of drug treatment doses is supported by previous reports (Peter and Rodan, 1999; Vahle et al., 2002). Female Sprague-Dawley rats (n = 47) were divided by body weight into untreated (no injection) OVX controls (n = 9), high-dose alendronate (H-ALN, n = 10, 2 mg/kg, 2×/week), low-dose alendronate (L-ALN, n = 9, 10 μg/kg, 2×/week), high-dose PTH (H-PTH, n = 10, 75 μg/kg, 5×/week), and low-dose PTH (L-PTH, n = 9, 0.3 μg/kg, 5×/week) groups. Rats were given access to a standard rodent chow and water ad libitum, were subjected to a 12:12 hour light: dark cycle, and were housed in 2 rats/cage in the same room. Rats were sacrificed at 12 months of age. Following sacrifice via isoﬂurane inhalation and cervical dislocation, femurs were dissected for use in this study and stored in saline at −20 °C until use. All animal procedures were approved by the Stony Brook University’s Institutional Animal Care and Use Committee.

2.2. Assessment of specimen and crack geometry

Cortical microbeams (~0.70 mm × 11.3 mm × 0.85 mm) were cut from the lateral quadrant of rat femur diaphyses using a low-speed diamond wafer blade (South Bay Technology, Inc.) based on protocols we used previously (Tommasini et al., 2012). Uneven surfaces were polished using fine 1500 grit sandpaper. Microbeams were notched on the perioseal side to approximately 20% of the width, following ASTM (2009, 2011) standards as closely as possible. Notches were made using a diamond wafer blade and then manually sharpened with a scalp knife. Microcomputed tomography (μCT) was used to measure bone geometry at 17.5 μm voxel size prior to testing as done previously (Scanco Medical AG, Brüttisellen, Switzerland) (Tommasini et al., 2012; Wallace et al., 2012). 3D rendered images of the area containing the bone notch were visualized and rotated directly in the microCT image viewer. Once the notch was identified, 2D images containing a bone slice showing full dimensions of the beams cross-section and showing the largest crack size were used to calculate crack dimensions. The notch depth was calculated as the difference in length from the edge of the microbeam to the notch, measured in the center of the microbeam. Specimen thickness, specimen width, and length were also measured from μCT images.

2.3. Measurement of mechanical properties

As measurement of rodent bone’s material properties are difficult to evaluate due to size constraints, we used a fracture mechanics approach for small animal models to measure cortical bone toughness. Microbeams were tested in 3-point bending tests in anatomically correct configuration with the notched side placed in tension (Fig. 1) to determine critical stress intensity factor, Kc, or fracture toughness at crack initiation. The span length was fixed at 3.2 mm. Testing was conducted under constant hydration with saline (Ritchie et al., 2008, 2010) using a micromechanical testing system (Electroforce 3200, TA Instruments, New Castle, DE). Bending tests were performed at a loading rate of 0.001 mm/s until failure occurred. Force-deformation curves, specimen geometry, and notch dimensions were used to calculate fracture toughness at crack initiation using Eqs. (1) and (2) as described by ASTM (2009, 2011) standards:

$$K_c = \frac{PS}{BWf\left(\frac{a}{W}\right)}$$  \hspace{1cm} (1)

$$f(a/W) = 3 - \frac{1.99 - \sqrt{\left(1 - \frac{a}{W}\right)\left(2.15 - 3.93\frac{a}{W} + 2.7\left(\frac{a}{W}\right)^2\right)}}{2\left(1 + 2\frac{a}{W}\right)(1 - \frac{a}{W})^3}$$  \hspace{1cm} (2)

With the variables defined as: P = load at initiation (A secant line
Fig. 1. Schematic diagram of the 3-point bending configuration for fracture toughness tests.

with 5% lower slope than the elastic modulus was plotted on the load-deformation curve, and its intersection with the curve was used to determine the load at initiation); $S =$ span length; $B =$ specimen thickness (measured along the side of the created notch); $W =$ specimen width (measured along the side that is perpendicular to the created notch); $a =$ crack size; and $f(\hat{d}) =$ geometrical shape factor.

2.4. Protein extraction

A small portion of cortical bone beam (7.45 mg ± 4.31 mg) was collected for protein extraction. Each specimen was first washed in cold nanopure water until free of blood. Specimens were defatted by three 15-minute washes in 500 μL of cold isopropyl ether under constant agitation. Liquid nitrogen was placed into a mortar and pestle unit and used to crush each specimen into a fine bone powder. The bone powders were then placed into microcentrifuge tubes.

Protein extraction and dialysis were conducted based on an established protocol (Sroga et al., 2011a, 2011b, Sroga and Vashishth, 2011). Briefly, 0.08 mL/mg of an extraction buffer (0.05 M tetrasodium EDTA, 4 M guanidine chloride, 30 mM Tris-HCL, 1 mg/mL BSA, 1 mL/L protease inhibitor, pH 7.4) was added to each microcentrifuge tube containing bone powders. A dialysis membrane (Spectrum Laboratories) was sealed between the tube and its lid (with hole), and the tubes were inverted into a beaker of extraction buffer. Protein extraction was conducted at 4 °C for 48 h. Specimen tubes were then transferred to beakers containing 1 x PBS with protease inhibitor. Dialysis was conducted at 4 °C for 120 h. The 1 x PBS solution was changed 3 times daily for the first 48 h, then once daily for the following 72 h. The extracts were centrifuged at 13,000 rpm for 30 min at 4 °C.

A portion of the supernatant was saved in −80 °C for enzyme-linked immunosorbent assays (ELISA). Another portion of the supernatant was vortexed and lyophilized for hydrolysis for AGEs measurement. Hydrolysis was conducted at 110 °C for 20 h (10 μL of 6 N HCL per 1 mg bone).

2.5. Quantification of non-collagenous proteins and advanced glycation end-products

Protein extracts were diluted 9370 x and 1875 x for measurement of osteopontin and osteocalcin, respectively, and proteins were quantified according to manufacturer’s protocols included with rat ELISA kits (Osteopontin: IBL-America, cat# 27360, Osteocalcin: Biomedical Technologies, cat# BT-490). A pre-assay with several dilutions of 2 randomly selected samples was performed to determine the dilution factors.

To measure total fluorescent AGEs, quinine standards and 200× diluted specimen hydrolysates were measured for fluorescence at 360/460 nm excitation/emission with a Synergy HT microplate reader (BioTek, Winooski, VT). A chloramine-T solution was added to hydroxyproline standards and specimen hydrolysates to oxidize hydroxyproline. A perchloric acid solution was then added to remove residual chloramine-T. Finally, a p-dimethylaminobenzaldehyde solution was added and incubated at 60 °C. Absorbance was measured on cooled specimens at 570 nm using the same microplate reader used in previous steps. Collagen content was calculated from hydroxyproline quantity for each specimen (Gross, 1958). Quinine fluorescence was then normalized to collagen content to measure total fluorescent AGEs.

2.6. Reflection-based Fourier Transform Infrared Microspectroscopy

Cortical bone from the lateral quadrant of the contralateral femur of each rat was analyzed using reflection-based Fourier Transform Infrared Microspectroscopy (FTIRM). Cortical bones were dehydrated in a series of ethanol washes and embedded in methyl methacrylate (PMMA) blocks. Hardened blocks were polished (Buehler, Lake Bluff, IL) with 1200 grit carbide paper and a cloth impregnated with diamond suspensions (particle size of 3, 1, 0.25, and 0.05 μm). Polishing on each sample was done for 3 min at each step. FTIRM was then conducted using a Nicolet Magna 860 Step-Scan FTIR spectrometer and Continuum IR microscope (Thermo Fisher Scientific, Waltham, MA). Data were collected in reflection mode (15 μm beam size, 4/cm resolution, 256 scans/pixel) from the surface of polished cortical bone. Spectra collected were analyzes for the ratio of non-reducible to reducible collagen crosslinks (peak height ratio 1660/1690 cm−1), linear baseline 1800 cm−1 and mineral crystallinity (peak height ratio 1020/1030 cm−1, linear baseline 930–1150 cm−1) using peak height ratios according to published protocols (Fig. 2) (Miller et al., 2007; Acerbo et al., 2014).

2.7. Statistical analyses

Shapiro-Wilk tests for normality were conducted for all variables. Fracture toughness, osteopontin, total fluorescent AGEs, and collagen maturity data were compared for 1) OVX vs ALN-treated groups and for 2) OVX vs PTH-treated groups with two separate One-Way ANOVA with Tukey post-hoc tests, while osteocalcin and mineral crystallinity were compared with two separate non-parametric Kruskal-Wallis with Dunn’s post-hoc tests. Multiple regression analyses to predict fracture toughness with non-collagenous proteins, total fluorescent AGEs, collagen maturity, and crystallinity were conducted for OVX vs ALN-treated groups and for OVX vs PTH-treated groups. Significance was determined based on $\alpha = 0.05$, and any $p$-values between 0.05 and 0.1 were considered as borderline significant. All statistical analyses were completed using Stata/IC 13.1 (StataCorp) and SPSS 26 (IBM).

3. Results

3.1. Alendronate treatment

Fracture toughness of the H-ALN group was greater than that of the OVX (+82.5%, $p \leq 0.01$) and L-ALN (+82.5%, $p \leq 0.01$) groups (Table 1, Fig. 3A). No differences were observed in AGE content between OVX and ALN-treated rats (Table 1, Fig. 3B). Osteocalcin was significantly greater in H-ALN rats compared to OVX rats (+32.1%, $p \leq 0.05$) and in H-ALN rats compared to L-ALN rats (+39.8%, $p \leq 0.05$) (Table 1, Fig. 3C). Osteopontin was greater in H-ALN rats compared to OVX rats (+133.9%, $p \leq 0.01$) and compared to L-ALN rats (+74.7%, $p \leq 0.05$) (Table 1, Fig. 3D). No differences were observed in mineral crystallinity.
or collagen maturity between OVX and ALN-treated groups (Table 1, Fig. 3E–F).

Multiple regression analyses indicated that in OVX and ALN-treated groups, 28% of the variance in fracture toughness was explained by non-collagenous proteins, total fluorescent AGEs, collagen maturity, and crystallinity as independent variables (full model: unadjusted $r^2 = 0.56$, adjusted $r^2 = 0.28$). Although it appeared that osteopontin alone was the significant predictor of fracture toughness ($p < 0.05$), the full multiple regression model itself was not significant ($p = 0.18$, Table 2).

### 3.2. Parathyroid hormone treatment

Fracture toughness for the H-PTH group was greater than that of the OVX (+60.2%, $p < 0.05$) and L-PTH (+49.6%, $p < 0.05$) groups (Table 1, Fig. 3A). Total fluorescent AGEs were significantly less in L-PTH rats compared to OVX (−34.2%, $p < 0.01$) and H-PTH rats (−42.4%, $p < 0.01$) (Table 1, Fig. 3B). There was no difference in osteocalcin between PTH groups and OVX (Table 1, Fig. 3C). Differences in OPN between groups were borderline significant with OPN being greater in the H-PTH (+176.6%, $p = 0.071$) and L-PTH (+176.2%, $p = 0.077$) groups compared to the OVX group (Table 1, Fig. 3D). There was higher mineral crystallinity in both the L-PTH group (+7.0%, $p ≤ 0.001$) and H-PTH group compared to OVX (+4.1%, $p ≤ 0.05$) (Table 1, Fig. 3E). The 4.6% decrease in collagen maturity in the L-PTH group compared to the OVX group was borderline significant ($p = 0.051$, Table 1, Fig. 3F).

In OVX and PTH-treated groups, fracture toughness was predicted by the independent variables (full model: unadjusted $r^2 = 0.60$, adjusted $r^2 = 0.41$, $p < 0.05$, Table 2) with osteocalcin ($p < 0.05$), osteopontin (p = 0.059), collagen maturity ($p ≤ 0.05$), and crystallinity ($p ≤ 0.05$) all being predictors of fracture toughness. Total fluorescent AGEs did not correlate with fracture toughness in the PTH treated group.

### 4. Discussion

We investigated the effect of bone matrix changes on fracture
produce both osteocalcin (Chenu et al., 1994; Barille et al., 1996) and osteopontin (Reinholt et al., 1990), further contributing to increased non-collagenous protein content with ALN treatment. Our study was limited in that rats do not undergo intracortical remodeling and we did not directly assess the effects of ALN on bone cell response or conduct histomorphometric analysis that could indicate the amount of bone resorbed or newly formed, which should be done in our future work.

ALN treatment increased fracture toughness, which represents the inherent resistance of a material to initiate the formation of a crack. The change in toughness found here may result from the increased production of osteocalcin and osteopontin due to ALN treatment. In support, we conducted a multiple regression analysis to identify the predictors of fracture toughness when an OVX model was treated with ALN. This analysis showed that osteopontin was the primary predictor of fracture toughness rather than AGE content, osteocalcin, mineral crystallinity, and collagen maturity as other possible factors. Hence, it seems that ALN treatment preserves osteopontin in the matrix and/or promotes secretion of more osteopontin via stimulation of osteoblasts as described above. Non-collagenous matrix proteins play an important role in bone fracture toughness by a collective interaction between osteocalcin and osteopontin that results in structural band formation and a consequent decrease in fracture toughness (Duvall et al., 2007; Thurner et al., 2010; Poundarik et al., 2012; Rodrigues et al., 2012; Poundarik et al., 2015). However, we found that only administration of a high dose of ALN, beyond clinical dosage, increased the fracture toughness of bone whereas fracture toughness of L-ALN treated rats was not significantly different from OVX controls. It is possible that the 6-month treatment at the lower, more clinically relevant dose of ALN, was not delivered for a long enough duration to measure the long-term effects of increased production of non-collagenous proteins and subsequent changes in toughness as was observed in the higher dose. Further work with low-dose ALN for longer treatment duration would clarify these results.

Intermittent delivery of PTH can stimulate bone growth through increased differentiation of osteoblasts or an anti-apoptotic effect on osteoblasts (Jilka et al., 1999; Datta and Abou-Samma, 2009; Osagie-Clouard et al., 2017), resulting in increased bone formation (Aslan et al., 2012). In support, we observed a trend for increased osteopontin in PTH-treated groups. Osteopontin is produced by osteoblasts (Reinholt et al., 1990), which can regulate mineral composition in the bone matrix (Poundarik et al., 2018), and plays an important role in fracture toughness through its interactions with osteocalcin (Duvall et al., 2007; Thurner et al., 2010, Poundarik et al., 2012, Rodrigues et al., 2012, Poundarik et al., 2015). Hence, because PTH stimulates osteoblasts, treatment with PTH will have a downstream effect of producing more osteopontin. As a result, bone will have increased ability to dissipate energy under applied loads to prevent crack propagation with a consequent improvement in bone fracture toughness (Hara et al., 2007; Poundarik et al., 2012; Bailey et al., 2017; Nikol et al., 2018; Poundarik et al., 2018). This assertion also supports the report of an increase in small pores in cortical bone in PTH-treated rats (Tommassini et al., 2012), where small pores can more effectively absorb shear forces than large pores (Cheng et al., 2009) and consequently prevent or reduce crack propagation (Herman et al., 2010).

PTH treatment increased fracture toughness, but only in the high PTH group. Given that PTH can increase bone mass and decrease fracture risk (Neer et al., 2001), this increase in bone fracture toughness is not surprising. The observed increase in non-collagenous protein content likely played a role for the increased fracture toughness in this group. In support, a multiple regression analysis conducted to identify predictors of fracture toughness when starting in an OVX condition and then being treated with PTH showed that non-collagenous proteins, collagen maturity, and crystallinity were predictors of fracture toughness.

Although there were no differences in collagen components (i.e., AGEs), we observed that AGEs were reduced in L-PTH group compared to H-PTH or OVX groups, with no change in fracture toughness. Moreover, although not statistically significant, there tended to be lower
collagen maturity in the L-PTH group compared to OVX controls. This suggests that 1) the L-PTH treated bone contained less mature collagen and consequently resulted in less AGE formation, and 2) AGEs do not significantly impact fracture toughness in an OVX rat model, which is supported by our multiple regression analyses (Table 2). Additionally, L-PTH rats had increased mineral crystallinity, which further supports the notion that PTH increases bone quantity in cortical bone, albeit through changes in mineral apposition (Sato et al., 2002). Increased mineral crystallinity as well as the decreased quantity of glycation-induced crosslinks found here would typically suggest improved bone toughness (Vashishth et al., 2001; Vashishth, 2005; Tang et al., 2007). Additional work is needed with low dose PTH at longer durations of treatment to help explain these findings.

Our fracture toughness analysis provided information on how matrix level changes affect the resistance of bone as a material while eliminating the effect of idealized assumptions used in whole bone fracture toughness tests (i.e., assuming femurs as idealized hollow cylinders). Nevertheless, this method has some inherent limitations that should be considered in the interpretation of the results. For example, our method measured fracture toughness or resistance of bone against the initiation of bone matrix degradation.
of a crack. Because bone is known to crack and not fracture, based on this data we cannot directly predict whether higher resistance to crack initiation will increase or decrease bone fragility. Previous studies on bone have demonstrated that the tendency of bone to form microdamage that does not coalesce into a fracture enhances toughness, while increased stress to initiate a crack that progresses into a fracture without collateral damage is the hallmark of brittle bone (Vashishth et al., 1997; Nalla et al., 2003).

In addition to the limitations stated above, further work is needed to assess other possibilities through which ALN or PTH treatment could impact fracture toughness including the impact of microarchitecture, degree of mineralization, other non-collagenous proteins, and specific AGEs. We previously reported in the same rats used in this study, that the lateral quadrant of femoral diaphyses had lower lacunae per tissue volume in ALN-treated rats compared to untreated OVX controls and comparatively more small pores in the tissue in PTH-treated rats (Tommasini et al., 2012). We also reported that ALN treatment but not PTH treatment mitigated the increased collagen alignment and reduced mineral crystal lengths due to OVX in new periosteal bone, while both treatments reduced mineral crystal width in existing intracortical bone (Acerbo et al., 2014). However, further work is needed to understand the direct effect of these factors on fracture toughness.

Despite these limitations, our results are largely consistent with previous clinical trials and prospective studies on post-menopausal women with bisphosphonates that show a reduction in fracture risk with an associated increase in bone mineral density (Bone et al., 2000; Reginster et al., 2000). While we found no change in glycation content under bisphosphonate treatment, work on other animal models showed that bisphosphonates increased glycation (Saito et al., 2008; Tang et al., 2009). AGEs accumulate in bone over time and previous studies used longer treatment duration (2–3 years) and a different animal model. Because AGE accumulation has been implicated in long-term treatment with bisphosphonate and in atypical femoral fractures, our data supports short-term treatment can minimize AGE accumulation in bone. This highlights the beneficial effects of non-collagenous proteins such as increase in content of osteocalcin and osteopontin with high ALN dose to increase fracture toughness while keeping accumulation of AGEs under control. In support, our multiple regression analyses indicated that fracture toughness can be predicted by non-collagenous proteins, collagen maturity, and crystallinity in OVX and PTH groups. Specifically, we found that the high-dose PTH group had increased fracture toughness that was explained in part by increased non-collagenous protein, osteopontin, in the matrix with no changes in AGEs. Low-dose PTH resulted in reduction of AGEs but no significant changes in osteocalcin and osteopontin content or increased fracture toughness. Such dose-specific differences have been previously reported in literature regarding the effect of PTH therapy on cortical bone (Compston, 2007). A few studies showed minimal or even negative effects while other studies showed beneficial effects of PTH treatment on cortical bone health (Jerome et al., 1999; Compston, 2007; Iwaniec et al., 2008; Ascenzi et al., 2012). Altogether, the current study demonstrated that treatments that enhance fracture toughness compared to OVX controls were attributed to increased presence of non-collagenous matrix proteins while minimizing the accumulation of AGEs in the cortical bone matrix.

Funding

Funding for this project was provided by National Institutes of Health projects under award numbers AR052778 (Judex) and AG20618 (Vashishth). One of the authors (Karim) was supported by an NIGMS T32 fellowship under award T32GM067545 for part of this work and is currently supported by NIAMS under award K01AR069685 (Karim).

CRediT authorship contribution statement

Lamy Karim: Methodology, Formal analysis, Investigation, Writing – original draft, Writing – review & editing, Visualization, Funding acquisition. Andrea Kwazala: Methodology, Investigation, Writing – original draft, Writing – review & editing. Deepak Vashishth: Conceptualization, Methodology, Resources, Writing – original draft, Writing – review & editing, Supervision, Project administration, Funding acquisition. Stefan Judex: Conceptualization, Methodology, Resources, Writing – original draft, Writing – review & editing, Supervision, Project administration, Funding acquisition.

Declaration of competing interest

None of the authors have conflicts of interest to disclose.

Acknowledgements

We thank Julie Russell for assistance in preparing microbeams for fracture toughness testing. Funding for this project was provided by National Institutes of Health projects under award numbers AR052778 (Judex) and AG20618 (Vashishth). One of the authors (Karim) was supported by an NIGMS T32 fellowship under award T32GM067545 for part of this work and is currently supported by NIAMS under award K01AR069685 (Karim). The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

References

2009 ASTM E399-09 Standard Test Method for Linear-elastic Plane-strain Fracture Toughness KIC of Metallic Materials, 2009, p. 33.
2011 ASTM E1120-11 Standard Test Method for Measurement of Fracture Toughness, 2011, p. 56.
Acerbo, A.S., Kwazala, A.T., Yang, L., Judex, S., Miller, L.M., 2014. Alterations in collagen and mineral nanostructure observed in osteoporosis and pharmaceutical treatments using simultaneous small- and wide-angle X-ray scattering. Calcif. Tissue Int. 95 (5), 446–456.
Allen, M., Burr, D., 2011. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don’t know. Bone 49, 56–65.
Allen, M.R., Gineys, E., Leeming, D.D., Burr, D.B., Delmas, P.D., 2008. Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebrae. Osteoporos.Int. 19 (3), 329–337.
Altundal, H., Ganryu, B., 2005. The influence of alendronate on bone formation after autogenous free bone grafting in rats. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 99 (3), 285–291.
Ascenzi, M.-G., Liao, V.P., Lee, B.M., Billi, F., Zhou, H., Lindsey, R., Cosman, F., Nieves, J., Bilezikian, J.P., Dempster, D.W., 2012. Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 27 (3), 702–712.
Aslan, D., Andersen, M.D., Gede, L.B., de Franca, T.K., Jorgensen, S.R., Schwarz, P., Jorgensen, N.R., 2012. Mechanisms for the bone abiotic effect of parathyroid hormone treatment in humans. Scand.J.Clin.Lab.Invest. 72 (1), 14–22.
Axelson, K.F., Wallander, M., Johansson, H., Lundh, D., Lorenzten, M., 2017. Hip fracture risk and safety with alendronate treatment in the oldest-old. J.Intern.Med. 282 (6), 546–559.
Bailey, S., Karsenty, G., Gundberg, C., Vashishth, D., 2017. Osteocalcin and osteopontin influence bone morphology and mechanical properties. Ann.N.Y.Acad.Sci. 1409 (1), 79–84.
Barille, S., Pellat-Deceunynck, C., Bataille, R., Amiot, M., 1996. Ectopic secretion of osteocalcin, the major non-collagenous bone protein, by the myeloma cell line NCI-H929. J. Bone Miner.Res. 11 (4), 466–471.
Bellows, C.G., Reimers, S.M., Heersche, J.N., 1999. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res. 297 (2), 249–259.
Black, D.M., Thompson, D.E., Bauer, D.C., Enrud, K., Mulsiner, T., Hochberg, M.C., Nevitt, M.C., Suryawanshi, S., Cummings, S.R., 2000. Fracture risk reduction with alendronate in women with osteoporosistherefractureinterventional study. J. Clin. Endocrinol. Metab. 85 (11), 4118–4124.
Boivin, G., Meunier, P.J., 2002. Effects of bisphosphonates on matrix mineralization. J. Musculoskeletal. Neuronal Interact. 2 (6), 538–543.
Bone, H.G., Greenspan, S.L., McKever, C., Bell, N., Davidson, M., Downs, R.W., Emkley, R., Meunier, P.J., Miller, S.S., Mulloy, A.L., Recker, R.R., Weijs, S.R., Heydens, N., Mulsiner, T., Suryawanshi, S., Yates, A.J., Lombardi, A., 2005.
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/estrogen study group. J.Clin.Endocrinol.Metab. 85 (2), 263–269.

Bone Reports 15 (2021) 101137

Jerome, C.P., Burr, D.B., Van Bibber, T., Hock, J.M., Brommage, R. 2001. Treatment with human parathyroid hormone (1–34) for 18 months increases cancellous bone volume and improves trabecular bone quality in patients with osteoporotic colostomy monkeys (Macaca fascicularis). Bone 26 (2), 150–159.

Burr, D.B., Allen, M.J., 2013. Academic Press.

Iwaniec, U.T., Trevisiol, C.H., Maddalozzo, G.F., Rosen, C.J., Turner, R.T., 2008. Effects of osteocalcin levels on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats. Bone Miner.Res. 24 (2), 209–220.

Hunt, H., Torres, A., Palomino, P., Marty, E., Saiyed, R., Cohn, M., Jo, J., Warner, S., Hernandez, C.J., Tang, S.Y., Baumbach, B.M., Hwu, P.B., Sakkee, A.N., van der Ham, F., Hara, K., Kobayashi, M., Akiyama, Y., 2007. Influence of bone osteocalcin levels on bone formation and osteoclast-like cell activity in a rat model for chronic alcohol abuse. Bone 42 (4), 695–701.

Cruces, C., Colucci, S., Grimaldi, M., Zigrino, F., Barattolo, R., Zambonin, G., Baldini, N., Vergnaud, P., Delmas, P.D., Zallone, A., 1994. Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. J. Cell Biol. 127 (4), 1149–1158.

Chenu, C., Cutroni, J.A., Cidade, G.A.G., Stucky, G.D., Morse, D.E., Hansma, P.K., 2005. Sacrificial bonds and hidden length dissipate energy as mineralized fibrils separate. J. Bone Miner. Res. 20 (10 Suppl. 1), S132 discussion S132-123.

Karim, L., Hussein, A.I., Morgan, E.F., Bouxsein, M.L., 2013. Increased bone formation by inhibition of protein precipitation in osteoblasts in rat tooth replantation model. J.Endocrinol. 219 (1), 207–215.

Kurland, E.S., Mahmoud, J.J., Rosen, C.J., Lindsay, R., Bilezikian, J.P., 2000. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J.Clin.Endocrinol.Metab. 85 (9), 3069–3076.

Morgan, E.F., Augat, P., 2016. Comparison of the safety and efficacy of denosumab and alendronate on non-enzymatic collagen cross-links and bone strength in postmenopausal women with osteoporosis. Osteoporos.Int. 24 (9), 2441–2447.

Karim, L., Vanhishai, D., 2013. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos.Int. 24 (9), 2441–2447.

Karim, L., Vanhishai, D., 2013. Heterogeneous glycosylation of cancellous bone and its association with bone quality and fragility. PLoS One 7 (4), e35047.

Karim, L., Hussein, A.I., Morgan, E.F., Bouxsein, M.L., 2013. In: Marcus, R., Feldman, D., Peter, C., Rodan, G.A., 1999. Preclinical safety profile of alendronate. Int. J. Clin. Pract. 53 (10), 1158–1164.

Karim, L., Augat, P., 2016. Dilatational band formation in bone. Proc.Natl.Acad.Sci.U.S.A. 113 (1), 207–212.

Karim, L., Moulton, J., Van Vliet, M., Velie, K., Robbins, A., Malekisopour, F., Abdeen, A., Ayres, D., Bouxsein, M.L., 2018. Bone microarchitecture, biomechanical properties, and advanced glycation end products in the proximal femur of adults with type 2 diabetes. Bone 114, 32–39.

Karim, L., Tang, S.Y., Sroga, G.E., Vanhishai, D., 2013. Differences in non-enzymatic glycation and collagen cross-links between human cortical and cancellous bone. Osteoporos.Int. 24 (9), 2441–2447.
Reginster, J., Minne, H.W., Sorensen, O.H., Hooper, M., Roux, C., Brandi, M.L., Lund, B., Ehgen, D., Pack, S., Roumagnac, I., Eastell, R., 2000. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebralfracturelifestyle with risedronate therapy (VERT) study group.

Osteoporos.Int. 11 (1), 83–91.

Reinholt, F.P., Hultenby, K., Oldberg, A., Heinegård, D., 1990. Osteopontin—a possible anchor of osteoclasts to bone. Proc.Natl.Acad.Sci.U.S.A. 87 (12), 4473–4477.

Ritchie, R.O., Koester, K.J., Ionova, S., Yao, W., Lane, N.E., Ager, J.W., 2008. Measurement of the toughness of bone: a tutorial with special reference to small animal studies. Bone 43 (5), 798–812.

Ritchie, R.O., Koester, K.J., Ionova, S., Yao, W., Lane, N.E., Ager, J.W., 2010. Erratum: measurement of the toughness of bone: a tutorial with special reference to small animal studies (Bone, vol. 43 (5), Nov. 2008, pp. 798-812). Bone 47 (3), 706.

Rodrigues, A.M., Caetano-Lopes, J., Vale, A.C., Vidal, B., Lopes, A., Aleixo, I., Pelido-Pereira, J., Sepriano, A., Perpetuo, I.P., Monteiro, J., Vaz, M.F., Fonseca, J.E., Canhão, H., 2012. Low osteocalcin/collagen type I bone gene expression ratio is associated with hip fracture risk. Bone 51 (6), 981–989.

Russell, R.G., Rogers, M.J., 1999. Bisphosphonates from the laboratory to the clinic and back again. Bone 25 (1), 97–106.

Sahni, M., Guenther, H.L., Fleisch, H., Collin, P., Martin, T.J., 1993. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J.Clin.Invest. 91 (5), 2004–2011.

Saito, M., Marumo, K., Kida, Y., Ushiku, C., Kato, S., Takao-Kawabata, R., Kuroda, T., 2011. Changes in the contents of enzymatic immature, mature, and non-enzymatic senescent cross-links of collagen after once-weekly treatment with human parathyroid hormone (1–34) for 18 months contribute to improvement of bone strength in ovariectomized monkeys. Osteoporos.Int. 22 (8), 2373–2383.

Saito, M., Mori, S., Mashiba, T., Komatsubara, S., Marumo, K., 2008. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with inacardone in dogs. Osteoporos.Int. 19 (9), 1343–1354.

Sato, M., Vahle, J., Schmidt, A., Westmore, M., Smith, S., Rowley, E., Ma, L.Y., 2002. Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 143 (9), 3239–3242.

Schwarz, P., Jorgensen, N.R., Moesklid, L., Ventergaard, P., 2012. Effects of increasing age, dosage, and duration of PTH treatment on BMD increase in rats. Endocrinology 143 (9), 3230–3239.

Shao, Y., Hernandez-Buquer, S., Childress, P., Stayrook, K.R., Alvarez, M.B., Davis, H., Schwarz, P., Jorgensen, N.R., Mosekilde, L., Vestergaard, P., 2012. Effects of increasing osteoporosis as detected by high resolution micro-CT. Bone 50 (3), 596–604.

Thomson, D.D., Simmons, H.A., Pirie, C.M., Ke, H.Z., 1995. FDA guidelines and animal models for osteoporosis. Bone 17 (4, Supplement), S525–S533.

Thurmer, P.J., Chen, C.G., Ionova-Martin, S., Sun, L., Harman, A., Porter, A., Ager, J.W., Ritchie, R.O., Alliston, T., 2010. Osteopontin deficiency increases bone fragility but preserves bone mass. Bone 46 (6), 1564–1573.

Tommassini, S.M., Trinward, A., Acerbo, A.S., De Carlo, F., Miller, L.M., Judex, S., 2012. Changes in intracortical microporosities induced by pharmaceutical treatment of osteoporosis as detected by high resolution micro-CT. Bone 50 (3), 596–604.

Ural, A., Vashishth, D., 2014. Hierarchical perspective of bone toughness—from molecules to fracture. Int.Mater.Rev. 59 (5), 245–263.

Vahle, J.J., Sato, M., Long, G.G., Young, J.K., Francis, P.C., Engelhardt, J.A., Westmore, M.S., Linda, Y., Nold, J.B., 2002. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol.Pathol. 30 (3), 312–321.

Valcourt, U., Merle, B., Ginets, E., Viguert-Carrin, S., Delmas, P.D., Garnett, P., 2007. Non-enzymatic glycation of bone collagen modifies osteostatic activity and differentiation. J.Biol.Chem. 282 (8), 5691–5703.

Vashishth, D., 2005. Collagen glycation and its role in fracture properties of bone. J.Musculoskelet. Neuronal Interact. 5 (4), 315–317.

Vashishth, D., Behr, J.C., Bonfield, W., 1997. Crack growth resistance in cortical bone: concept of microcrack toughening. J.Biomech. 30 (8), 763–769.

Vashishth, D., Gibson, G.J., Khoury, J.J., Schaffer, M.B., Kimura, J., Fyhrie, D.P., 2001. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 28 (2), 195–201.

Viguert-Carrin, S., Farlay, D., Bala, Y., Munoz, F., Bouxein, M.L., Delmas, P.D., 2008. In an in vitro model to test the contribution of advanced glycation end products to bone biomechanical properties. Bone 42 (1), 139–149.

Wallace, I.J., Tommassini, S.M., Judex, S., Garland Jr., T., Demes, B., 2012. Genetic variations and physical activity as determinants of limb bone morphology: an experimental approach using a mouse model. Am.J.Phys.Anthropol. 148 (1), 14–35.

Xiong, Y., Yang, H.J., Feng, J., Shi, Z.L., Wu, L.D., 2009. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J.Int.Med. Res. 37 (2), 407–416.

Xu, Z., Zhu, C., Xia, R., Shang, X., 2019. Alendronate stimulates osteoblast differentiation through PPAR-STAT3 and STAT1 in an osteoporosis rat model. Int.J.Clin.Exp.Med. 12 (10), 12150–12157.

Xu, Z., Mostafa, A., Appleford, M., Sun, L.W., Wang, X., 2016. Bone formation is affected by matrixadvancedglycationendproducts (AGEs) in vivo. Calcif. Tissue Int. 99 (4), 373–383.

Yu, Z., Wang, G., Tan, T., Fu, L., Yu, X., Zhu, Z., Dai, K., 2015. Long-term effects of ovariectomy on the properties of bone in goats. Exp. Ther. Med. 9 (5), 1967–1973.